Patents Assigned to Genentech
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20160052940
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 25, 2016
    Applicant: GENENTECH, INC.
    Inventors: ANTHONY ESTRADA, LITING DONG, KEVIN X. CHEN, PAUL GIBBONS, MALCOLM HUESTIS, TERRY KELLAR, WEN LIU, CHANGYOU MA, JOSEPH LYSSIKATOS, ALAN OLIVERO, SNAHEL PATEL, DANIEL SHORE, MICHAEL SIU
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE
    Publication number: 20160051550
    Abstract: The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Application
    Filed: August 26, 2015
    Publication date: February 25, 2016
    Applicant: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
    Patent number: 9266903
    Abstract: The present invention relates to crystalline polymorphs of (2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (GDC-0032, taselisib), methods of use, and processes of preparing thereof.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: February 23, 2016
    Assignee: Genentech, Inc.
    Inventor: Jeffrey Stults
  • Anti-Bv8 antibodies and uses thereof
    Patent number: 9266948
    Abstract: The present invention concerns antibodies to Bv8 and the uses of same.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: February 23, 2016
    Assignee: Genentech, Inc.
    Inventors: Xiumin Wu, Van Wu, Lanlan Yu, Napoleone Ferrara, Wei-Ghing Liang, Yu-Ju G. Meng, Janet Tien
  • Biheteroaryl compounds and uses thereof
    Patent number: 9266862
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: February 23, 2016
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Alan G. Olivero, Snahel Patel, Michael Siu
  • Anti-FGFR4 antibodies and methods of use
    Patent number: 9266955
    Abstract: The invention provides anti-FGFR4 antibodies and methods of using the same.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: February 23, 2016
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Luc Desnoyers, Dorothy French
  • Gram-positive bacteria specific binding compounds
    Patent number: 9266943
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: February 23, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Anti-PCSK9 antibodies, formulations, dosing, and methods of use
    Patent number: 9266961
    Abstract: The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: February 23, 2016
    Assignee: Genentech, Inc.
    Inventors: Yan Wu, Cecilia Pui Chi Chiu, Daniel K. Kirchhofer, Andrew Peterson, Ganesh A. Kolumam, Monica Kong Beltran, Paul Moran, Wei Li, Xanthe M. Lam, Lin Luis, Ada Hui
  • C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses
    Publication number: 20160046608
    Abstract: The present invention provides for pyrimidine compounds of Formula I-I and embodiments thereof In Formula I-I in which R1, R2, R3, R4, R5, R6, m, n and the “het” ring are as described herein. Also provided are pharmaceutical compositions comprising compounds of Formula I and methods of using such compounds and compositions.
    Type: Application
    Filed: October 30, 2015
    Publication date: February 18, 2016
    Applicant: Genentech, Inc.
    Inventors: Frederick Cohen, Snahel Patel
  • MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
    Publication number: 20160045515
    Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.
    Type: Application
    Filed: July 6, 2015
    Publication date: February 18, 2016
    Applicant: Genentech, Inc.
    Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
  • Serine/threonine kinase inhibitors
    Patent number: 9259470
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: February 16, 2016
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
    Patent number: 9260415
    Abstract: Heteroaryl pyridone and aza-pyridone amide compounds with electrophilic functionality of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: February 16, 2016
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, BinQing Wei, Wendy B. Young
  • CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR MODULATOR
    Publication number: 20160039770
    Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the estrogen receptor modulator (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid. Also described are pharmaceutical compositions suitable for administration to a mammal that include the estrogen receptor modulator, and methods of using the estrogen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with estrogen receptor activity.
    Type: Application
    Filed: August 10, 2015
    Publication date: February 11, 2016
    Applicant: GENENTECH, INC.
    Inventors: Nicholas D. Smith, Mark R. Herbert
  • Compositions and methods for stabilizing protein-containing formulations
    Patent number: 9254321
    Abstract: The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 9, 2016
    Assignee: Genentech, Inc.
    Inventors: Osigwe Esue, Vikas K. Sharma
  • RON COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160032013
    Abstract: This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.
    Type: Application
    Filed: May 29, 2015
    Publication date: February 4, 2016
    Applicant: GENENTECH, INC.
    Inventors: JACKSON G. EGEN, JO-ANNE HONGO, STEVEN KAUDER, ROBERT A. LAZARUS, LYDIA SANTELL, YAN WU, MEREDITH HAZEN, WEI-CHING LIANG
  • Protein purification
    Patent number: 9249218
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: February 2, 2016
    Assignee: GENENTECH, INC.
    Inventors: Carol D. Basey, Greg S. Blank
  • Anti-EPHB4 antibodies and methods using same
    Patent number: 9249222
    Abstract: The invention provides anti-EphB4 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: February 2, 2016
    Assignee: Genentech, Inc.
    Inventors: Yan Wu, Minhong Yan
  • Pyridinones/pyrazinones, method of making, and method of use thereof
    Patent number: 9249123
    Abstract: Pyridone and pyrazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: February 2, 2016
    Assignees: Genentech, Inc., Gilead Connecticut, Inc.
    Inventors: Kevin S. Currie, Xiaojing Wang, Wendy B. Young
  • TREATING TH2-MEDIATED DISEASES BY INHIBITION OF BROMODOMAINS
    Publication number: 20160024504
    Abstract: The invention provides methods for treating Th2 cytokine-mediated diseases by inhibiting bromodomain function.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicants: CONSTELLATION PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Benjamin Fauber, Hon-Ren Huang, Jose M. Lora, Steven Magnuson, Christopher G. Nasveschuk, Andres Salmeron, Robert J. Sims, III, Alexander M. Taylor
  • PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA
    Publication number: 20160024217
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Application
    Filed: March 26, 2015
    Publication date: January 28, 2016
    Applicant: GENENTECH, INC.
    Inventors: Martin GAWLITZEK, Shun LUO, Christina Teresa PETRAGLIA